Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Asia More “Enlightened” Regulatory Environment – Pharmaxis CEO

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Sydney-based Pharmaxis will submit its marketing authorization application for chronic lung condition drug Bronchitol to Australia's Therapeutic Good Administration in the third quarter of 2008

You may also be interested in...



PharmAsia News Australia/New Zealand Roundup: Medicines Australia, PHARMAC, Helicon, Pharmaxis

Medicines Australia Critical Of Labor Government's First Budget

PharmAsia News Australia/New Zealand Roundup: Medicines Australia, PHARMAC, Helicon, Pharmaxis

Medicines Australia Critical Of Labor Government's First Budget

Aussie Pharma Pharmaxis Submits Bronchitol Application to China’s State FDA

PERTH, Australia - Sydney-based Pharmaxis submitted a clinical trial application to China's State FDA for chronic lung condition drug Bronchitol (mannitol) for treatment of bronchiectasis, the company announced March 7

Table

View full table

Tags:
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC067674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By